Difference between revisions of "Afatinib (Gilotrif)"
Jump to navigation
Jump to search
m (Jwarner moved page Afatinib (Gliotrif) to Afatinib (Gilotrif): Misspelled!) |
Warner-admin (talk | contribs) m (Text replacement - "(Gliotrif)" to "(Gilotrif)") |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Irreversible tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor, ErbB1), HER2 (human epidermal growth factor receptor 2, ErbB2), and HER4 (human epidermal growth factor receptor 4, ErbB4). Inhibition of tyrosine kinase autophosphorylation inhibits ErbB signaling.<ref name=insert>[http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Gilotrif/Gilotrif.pdf Afatinib ( | + | Class/mechanism: Irreversible tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor, ErbB1), HER2 (human epidermal growth factor receptor 2, ErbB2), and HER4 (human epidermal growth factor receptor 4, ErbB4). Inhibition of tyrosine kinase autophosphorylation inhibits ErbB signaling.<ref name=insert>[http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Gilotrif/Gilotrif.pdf Afatinib (Gilotrif) package insert]</ref><ref>[[Media:Afatinib.pdf | Afatinib (Gilotrif) package insert (locally hosted backup)]]</ref><ref>[http://www.gilotrif.com/ Gliotrif manufacturer's website]</ref> |
Route: PO | Route: PO | ||
| Line 12: | Line 12: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Gilotrif/Gilotrif.pdf Afatinib ( | + | *[http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Gilotrif/Gilotrif.pdf Afatinib (Gilotrif) package insert]<ref name="insert"></ref> |
| − | *[http://chemocare.com/chemotherapy/drug-info/afatinib.aspx Afatinib ( | + | *[http://chemocare.com/chemotherapy/drug-info/afatinib.aspx Afatinib (Gilotrif) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/afatinib.aspx Afatinib (Gilotrif) patient drug information (Chemocare)]</ref> |
| − | *[http://www.uptodate.com/contents/afatinib-patient-drug-information Afatinib ( | + | *[http://www.uptodate.com/contents/afatinib-patient-drug-information Afatinib (Gilotrif) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/afatinib-patient-drug-information Afatinib (Gilotrif) patient drug information (UpToDate)]</ref> |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Revision as of 00:14, 27 October 2017
General information
Class/mechanism: Irreversible tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor, ErbB1), HER2 (human epidermal growth factor receptor 2, ErbB2), and HER4 (human epidermal growth factor receptor 4, ErbB4). Inhibition of tyrosine kinase autophosphorylation inhibits ErbB signaling.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Afatinib (Gilotrif) package insert[1]
- Afatinib (Gilotrif) patient drug information (Chemocare)[4]
- Afatinib (Gilotrif) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 7/12/2013: FDA approved for "the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test."
Also known as
- Code names: BIBW 2992, BIBW-2992
- Brand names: Afanix, Gilotrif, Giotrif, Tomtovok, Tovok, Xovoltib